[HTML][HTML] Hyperthermic laser ablation of recurrent glioblastoma leads to temporary disruption of the peritumoral blood brain barrier
Background Poor central nervous system penetration of cytotoxic drugs due to the blood
brain barrier (BBB) is a major limiting factor in the treatment of brain tumors. Most recurrent …
brain barrier (BBB) is a major limiting factor in the treatment of brain tumors. Most recurrent …
Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκB
MA Amin, CS Haas, K Zhu, PJ Mansfield, MJ Kim… - Blood, 2006 - ashpublications.org
Cell adhesion molecules are critical in monocyte (MN) recruitment in immune-mediated and
hematologic diseases. We investigated the novel role of recombinant human migration …
hematologic diseases. We investigated the novel role of recombinant human migration …
The briefing, intraoperative teaching, debriefing model for teaching in the operating room
NK Roberts, RG Williams, MJ Kim… - Journal of the …, 2009 - journals.lww.com
The need for a more deliberate approach to operating room teaching becomes more imperative
as duty hour restrictions limit the exposure residents have to the operating room. A good …
as duty hour restrictions limit the exposure residents have to the operating room. A good …
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection
JH Kim, JL Excler, NL Michael - Annual review of medicine, 2015 - annualreviews.org
RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1 acquisition.
The prespecified analysis of immune correlates of risk showed that antibodies directed …
The prespecified analysis of immune correlates of risk showed that antibodies directed …
HIV vaccines: lessons learned and the way forward
…, S Rerks-Ngarm, JL Excler, NL Michael - Current Opinion in HIV …, 2010 - journals.lww.com
Future HIV vaccine trials should define the RV144 immune responses relevant to protection,
improve durability and level of protection, and assess efficacy in diverse risk groups. New …
improve durability and level of protection, and assess efficacy in diverse risk groups. New …
Human immunodeficiency virus vaccine trials
…, JH Kim, L Corey, NL Michael - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
More than 2 million AIDS-related deaths occurred globally in 2008, and more than 33 million
people are living with HIV/AIDS. Despite promising advances in prevention, an estimated …
people are living with HIV/AIDS. Despite promising advances in prevention, an estimated …
Measurement of neutrino oscillations with the MINOS detectors in the NuMI beam
…, D Jensen, T Kafka, SMS Kasahara, JJ Kim, MS Kim… - Physical Review Letters, 2008 - APS
This Letter reports new results from the MINOS experiment based on a two-year exposure to
muon neutrinos from the Fermilab NuMI beam. Our data are consistent with quantum-…
muon neutrinos from the Fermilab NuMI beam. Our data are consistent with quantum-…
Bts: An accelerator for bootstrappable fully homomorphic encryption
Homomorphic encryption (HE) enables the secure offloading of computations to the cloud
by providing computation on encrypted data (ciphertexts). HE is based on noisy encryption …
by providing computation on encrypted data (ciphertexts). HE is based on noisy encryption …
[HTML][HTML] Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
…, NL Michael, P Kunasol, JH Kim - … England Journal of …, 2009 - Mass Medical Soc
Background The development of a safe and effective vaccine against the human immunodeficiency
virus type 1 (HIV-1) is critical to pandemic control. Methods In a community-based, …
virus type 1 (HIV-1) is critical to pandemic control. Methods In a community-based, …
[HTML][HTML] Immune-correlates analysis of an HIV-1 vaccine efficacy trial
…, S Rerks-Ngarm, NL Michael, JH Kim - … England Journal of …, 2012 - Mass Medical Soc
Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
